Aclaris Therapeutics Inc ACRS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ACRS is a good fit for your portfolio.
News
-
Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update
-
Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
-
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)
-
Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
-
Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor
Trading Information
- Previous Close Price
- $0.87
- Day Range
- $0.84–0.93
- 52-Week Range
- $0.59–18.54
- Bid/Ask
- $0.88 / $0.91
- Market Cap
- $64.01 Mil
- Volume/Avg
- 3.5 Mil / 3.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.81
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Core
- Total Number of Employees
- 105
- Website
- https://www.aclaristx.com
Valuation
|
Metric
|
ACRS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.40 |
Price/Sales | 2.81 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ACRS
|
|---|---|
Quick Ratio | 3.78 |
Current Ratio | 4.50 |
Interest Coverage | — |
Quick Ratio
ACRS
Profitability
|
Metric
|
ACRS
|
|---|---|
Return on Assets (Normalized) | −34.30% |
Return on Equity (Normalized) | −44.46% |
Return on Invested Capital (Normalized) | −44.32% |
Return on Assets
ACRS
Diagnostics & Research Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Mbk | $191.5 Bil | |
DHR
| Danaher Corp | Nczfxs | $165.0 Bil | |
IQV
| IQVIA Holdings Inc | Jhrrnc | $39.1 Bil | |
IDXX
| IDEXX Laboratories Inc | Pjrwgn | $38.7 Bil | |
A
| Agilent Technologies Inc | Sdtd | $37.3 Bil | |
MTD
| Mettler-Toledo International Inc | Xwrntx | $23.7 Bil | |
ICLR
| Icon PLC | Kdysl | $22.0 Bil | |
LH
| Laboratory Corp of America Holdings | Hzccbcd | $18.4 Bil | |
WAT
| Waters Corp | Tvgj | $16.6 Bil | |
ILMN
| Illumina Inc | Btwhg | $16.2 Bil |